• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Plecanatide Is Efficacious in Patients With Irritable Bowel Syndrome With Constipation and Bloating: Evaluation Using Trisymptom Composite Endpoints.

出版信息

Gastroenterol Hepatol (N Y). 2024 Dec;20(12 Suppl 9):12-13.

PMID:39896921
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11784541/
Abstract
摘要

相似文献

1
Plecanatide Is Efficacious in Patients With Irritable Bowel Syndrome With Constipation and Bloating: Evaluation Using Trisymptom Composite Endpoints.普卡那肽对伴有便秘和腹胀的肠易激综合征患者有效：使用三症状复合终点进行评估。
Gastroenterol Hepatol (N Y). 2024 Dec;20(12 Suppl 9):12-13.
2
Plecanatide Improves Abdominal Bloating and Bowel Symptoms of Irritable Bowel Syndrome with Constipation.普卡必利改善便秘型肠易激综合征的腹胀和肠道症状。
Dig Dis Sci. 2024 May;69(5):1731-1738. doi: 10.1007/s10620-024-08330-y. Epub 2024 Apr 9.
3
Plecanatide Improves Symptoms of Irritable Bowel Syndrome with Constipation: Results of an Integrated Efficacy and Safety Analysis of Two Phase 3 Trials.普卡那肽改善便秘型肠易激综合征症状：两项3期试验的综合疗效与安全性分析结果
Int J Gen Med. 2023 Aug 25;16:3769-3777. doi: 10.2147/IJGM.S400431. eCollection 2023.
4
Efficacy and Tolerability of Guanylate Cyclase-C Agonists for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis.鸟苷酸环化酶 C 激动剂治疗便秘型肠易激综合征和慢性特发性便秘的疗效和耐受性：系统评价和荟萃分析。
Am J Gastroenterol. 2018 Mar;113(3):329-338. doi: 10.1038/ajg.2017.495. Epub 2018 Jan 30.
5
Plecanatide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: Post hoc analyses of placebo-controlled trials in adults with severe constipation.普卡必利治疗慢性特发性便秘和便秘型肠易激综合征：成人严重便秘安慰剂对照试验的事后分析。
Neurogastroenterol Motil. 2023 Sep;35(9):e14632. doi: 10.1111/nmo.14632. Epub 2023 Jun 18.
6
Evaluation of Plecanatide for the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation in Patients 65 Years or Older.评价普卡那肽治疗 65 岁及以上慢性特发性便秘和便秘型肠易激综合征患者的疗效。
Clin Ther. 2020 Jul;42(7):1406-1414.e4. doi: 10.1016/j.clinthera.2020.05.012. Epub 2020 Jul 10.
7
Plecanatide for Treatment of Chronic Constipation and Irritable Bowel Syndrome.普卡必利治疗慢性便秘和肠易激综合征。
Am J Med. 2019 May;132(5):572-575. doi: 10.1016/j.amjmed.2018.11.027. Epub 2018 Dec 11.
8
Plecanatide for the treatment of constipation-predominant irritable bowel syndrome.普卡必利治疗便秘型肠易激综合征。
Expert Rev Gastroenterol Hepatol. 2020 Feb;14(2):71-84. doi: 10.1080/17474124.2020.1722101. Epub 2020 Feb 5.
9
Efficacy and safety of plecanatide in treating constipation predominant irritable bowel syndrome.普卡那肽治疗便秘型肠易激综合征的疗效与安全性。
Expert Opin Pharmacother. 2018 Feb;19(2):177-183. doi: 10.1080/14656566.2018.1427733. Epub 2018 Jan 29.
10
Healthcare Utilization and Costs of Care in Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation After Initiating Oral Therapies: Real-World Analysis in the US Medicare Population.便秘型肠易激综合征或慢性特发性便秘患者开始口服治疗后的医疗保健利用情况及护理费用：美国医疗保险人群的真实世界分析
Adv Ther. 2025 May;42(5):2500-2512. doi: 10.1007/s12325-025-03163-1. Epub 2025 Mar 28.

引用本文的文献

1
Patient-Centered Approach in IBS-C Management.肠易激综合征便秘型管理中的以患者为中心的方法
Gastroenterol Hepatol (N Y). 2025 Jun;21(6):362-373.
2
Raising Expectations in IBS-C Management.提高IBS-C管理的期望。
Gastroenterol Hepatol (N Y). 2025 Apr;21(4):218-231.